Showing results (91-100 of 139) with videos related to
Sort By:
Pageof 14
Journal of the National Cancer Institute|April 7, 2017
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic AdenocarcinomaAngélique Vienot, Guillaume Beinse, Christophe Louvet, et al.Cancer Medicine|July 18, 2019
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trialEmilie Charton, Jean-Baptiste Bachet, Pascal Hammel, et al.The Lancet. Gastroenterology & Hepatology|April 12, 2017
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trialJean-Baptiste Bachet, Pascal Hammel, Jérôme Desramé, et al.European Journal of Cancer (Oxford, England : 1990)|June 4, 2013
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinomaJean-Baptiste Bachet, Raphael Maréchal, Pieter Demetter, et al.European Journal of Cancer (Oxford, England : 1990)|February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studiesJulien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.Cancer Medicine|January 26, 2016
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancerBenoist Chibaudel, Frédérique Maindrault-Gœbel, Jean-Baptiste Bachet, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France TrialJulien Taieb, Valérie Taly, Julie Henriques, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2022
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II StudyThierry André, David Tougeron, Guillaume Piessen, et al.Pageof 14